Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement

Published: Monday, August 06, 2012
Last Updated: Monday, August 06, 2012
Bookmark and Share
Myriad will assess BRCA status in phase II study.

Myriad Genetics, Inc. announced that it has signed an agreement with Pharma Mar, a leader in the development of marine-derived drugs. Under the agreement, Myriad will conduct BRCA 1 and BRCA 2 testing on patients to be enrolled in a Phase II clinical study of PM1183, a novel drug candidate which induces double-stranded DNA breaks to cause cell death.

"PM1183 is an exciting compound, and we are extremely pleased to be working with Pharma Mar on this project," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "We believe this agreement, as well as our many other companion diagnostic projects for DNA-damaging agents, demonstrates the importance of a patient's BRCA status in identifying potential responders to this class of drugs."

Under the agreement, Myriad will assess the BRCA status in patients who respond to PM1183. Myriad has entered into similar agreements with Abbott Pharmaceuticals, Astra Zeneca, BioMarin Pharmaceuticals and Cephalon to provide companion diagnostic testing with the BRACAnalysis(R) test for clinical trial enrollment.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Myriad Acquires Sividon Diagnostics
Acquisition strengthens market leading oncology product portfolio with breast cancer prognostic test EndoPredict®.
Wednesday, June 01, 2016
Clinical Utility of Myriad myPath(TM) Melanoma Test Demonstrated
Test reduced indeterminate cases by 76 percent and changed treatment in 35 percent of cases.
Wednesday, September 10, 2014
Myriad Genetics Receives the Charles R. Smart Visionary Award
Company receives 2012 Charles R. Smart Visionary award from the American Cancer Society's.
Monday, June 11, 2012
Myriad Genetics Acquires Exclusive Rights to RAD51C Cancer Gene
Mutations in the RAD51C gene have been linked to an increased risk for developing hereditary breast and ovarian cancers.
Friday, January 20, 2012
Scientific News
Implementation Science Approaches to Reduce Mother-to-Child HIV Transmission
The NIH study will investigate best practices to ease major disease burden in Sub-Saharan Africa.
Portable Test Rapidly Detects Zika
To better diagnose and track the disease, scientists are now reporting a new $2 test that in the lab can accurately detect low levels of the virus in saliva.
New Nanoparticle Technology Developed to Treat Aggressive Thyroid Cancer
Researchers from Brigham and Women’s Hospital have developed a nanoplatform that can deliver RNAi agents to sites of anaplastic thyroid cancer.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Faster Detection of Pathogens in the Lungs
Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
£14m EU Project To Aid Meningitis Diagnosis and Cut Antibiotic Use
An international team of doctors are aiming to develop a rapid test to allow medics to quickly identify bacterial infection in children.
Bringing AFM to Medical Diagnostics
Company has announced that its NanoWizard® AFM and ForceRobot® systems are being used in the field of medical diagnostics in the Supersensitive Molecular Layer Laboratory of POSTECH in Korea.
Scientific Gains May Make Electronic Nose the Next Everyday Device
UT Dallas team breathes new life into possibilities by using CMOS integrated circuits technology.
Electronic Sensor Tells Dead Bacteria From Live
The sensor, which measures 'osmoregulation', is a potential future tool for medicine and food safety.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!